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ABSTRACT Master developmental pathways, such as Notch, Wnt, and Hedgehog, are signaling systems that control proliferation, cell death,
motility, migration, and stemness. These systems are not only commonly activated in many solid tumors, where they drive or
contribute to cancer initiation, but also in primary and metastatic tumor development. The reactivation of developmental
pathways in cancer stroma favors the development of cancer stem cells and allows their maintenance, indicating these signaling
pathways as particularly attractive targets for efficient anticancer therapies, especially in advanced primary tumors and metastatic
cancers. Metastasis is the worst feature of cancer development. This feature results from a cascade of events emerging from the
hijacking of epithelial-mesenchymal transition, angiogenesis, migration, and invasion by transforming cells and is associated with
poor survival, drug resistance, and tumor relapse. In the present review, we summarize and discuss experimental data suggesting
pivotal roles for developmental pathways in cancer development and metastasis, considering the therapeutic potential. Emerging
targeted antimetastatic therapies based on Notch, Wnt, and Hedgehog pathways are also discussed.
KEYWORDS Cancer metastasis; developmental pathways; Notch; Wnt; Hedgehog; therapeutic targets
 
Introduction
The  development  of  metastasis  from  a  primary  tumor  site,
including  epithelial-mesenchymal  transition  (EMT),  tumor
neoangiogenesis,  and  spread  of  malignancy,  is  a  multistep
phenomenon for targeting tissues and organs. The spread of
malignancy  results  from  malignant  cell  transport  through
blood vessels to target tissues and organs, the invasion of the
latter by infiltrating malignant cells,  and the development of
secondary  tumors1,2.  Master  developmental  pathways,  such
as  Notch,  Wnt,  and  Hedgehog,  are  signaling  pathways  that
play pivotal roles along embryonic development. The role of
Notch  in  solid  tumor  and  hematological  malignancy  in-
itiation  and  development  has  been  extensively  documented.
In  most  cases,  Notch  is  a  major  oncogene  associated  with
tumor  progression  to  metastasis,  anoikis  resistance,  EMT,
neoangiogenesis, malignant cell proliferation, and changes in
tissue  microenvironment  promoting  the  homing  of  me-
tastasis-promoting cells; nonetheless, Notch may also act as a
tumor suppressor3-6.
The overexpression of Wnt signaling is common in many
hematological malignancies and solid tumors. Clinical and
experimental evidence suggests that Wnt/β-catenin activation
is critical for cancer development, angiogenesis, migration,
and invasion5-7.  The antagonists of Wnt pathway, such as
Wnt inhibitory factor 1 (WIF-1), Dickkopf proteins (Dkks),
the  secreted  frizzled-related  proteins  (sFRPs),  and  Di-
sheveled-axin domain containing 1 (DIXDC1), enhance the
tumorigenic and metastatic processes of various cancer types
in vitro and in vivo8-10. Similar to Notch and Wnt pathways,
Hedgehog is  an evolutionary and developmental  pathway
involved  not  only  in  cellular  differentiation  but  also  in
physiological and tumorigenic control of postnatal cellular
events, such as proliferation, cell death, motility, migration,
and invasion5,6.
Emerging  therapies  targeting  master  developmental
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pathways  represent  promising  approaches  for  metastasis
prevention and cancer stem cell elimination (Figure 1). In
this  study,  we  summarize  the  data  supporting  a  role  for
developmental  pathways  in  pro-metastatic  processes,
emphasizing on Notch,  Wnt,  and Sonic  Hedgehog (Shh),
considering  their  therapeutic  potential.  Emerging  an-
timetastatic  strategies  targeting  these  developmental
pathways are also discussed.
Pro-metastatic changes and
developmental pathways
Resistance to anoikis
Similar  to  other  anchorage-dependent  cells,  the  survival  of
tumor  cells,  following  the  detachment  from  surrounding
epithelial  tissue  or  extracellular  matrix,  requires  the  ca-
pability  to  resist  against  the  form of  programmed cell  death
resulting  from  such  detachment,  namely,  anoikis.  Unlike
most  normal  anchorage-dependent  cells  that  undergo  cell
death  when  detached  from  the  extracellular  matrix,  tumor
cells  can  implement  several  molecular  mechanisms,  pro-
moting  their  survival  in  suspension  and  the  spread  of
metastases.  The  experimental  and  clinical  evidence  strongly
suggests  that  the  subversion  of  the  repertoire  of  integrin
developmental  pathways  is  the  main  molecular  mechanism
favoring anoikis resistance in tumor cells.
Cell-cell  and cell-extracellular  matrix  contacts  support
anchorage-dependent cell survival in an integrin-dependent
manner, partly because of integrin-mediated activation of
anti-apoptotic signaling pathways, such as phosphoinositide
3-kinase (PI3K)/protein kinase B (Akt), mitogen-activated
protein  kinase  (MAPK),  and  focal  adhesion  kinase
pathways11,12. The aberrant constitutive activation of these
anti-apoptotic  signaling  pathways  results  in  post-trans-
lational modifications and changes in the levels of Bcl-2 anti-
apoptotic protein family members, i.e., multi-domain and
BH3  domain-only  proteins.  Consequently,  the  over-
expression of the latter proteins in tumor cells prevents the
mitochondrial  function disruptions that normally lead to
programmed cell death13 and related pro-apoptotic mech-
anisms, such as metabolism-induced autophagy11,12.
In  addition  to  these  intrinsic  apoptotic  mechanisms,
metastatic competent cells also achieve resistance to anoikis
and anticancer therapy by interfering with extrinsic apoptosis
pathways, such as the families of death receptors, including
Fas  receptors13.  Notably,  the  prevention  of  Fas  receptor
activity results in increased levels of cellular FADD-like IL-
1β-converting  enzyme-inhibitory  protein,  a  master  anti-
apoptotic regulator, in these tumor cells. This increase results
in  a  cross  talk  between  extrinsic  and  intrinsic  caspase
pathways that impair the capability to use common apoptotic
caspases, particularly effector caspases, favoring tumor cell
survival13.  Integrin  signaling has  the  capability  to  induce
ligand-independent activation of developmental signaling
molecules  that  are  able  to  trigger  resistance  to  anoikis.
Examples include the loss in cell adhesion factors, such as E-
cadherin;  and the  overactivation  of  other  EMT signaling
molecules,  such  as  the  mammalian  target  of  rapamycin
(mTORC1  and  mTORC2)14-16,  growth  factors,  such  as
epidermal  growth  factor  (EGF)  and  vascular  endothelial
growth factor (VEGF) receptor signaling pathways12-15, and
oncogenes, such as Wnt, β-catenin, Notch, and Shh17-20.
The  potential  of  the  pharmacological  targeting  of
developmental  signaling  pathways  favoring  resistance  to
anoikis supports the survival of metastatic cells throughout
 
Figure 1   Effects of conventional anticancer drugs and of their combination with emerging therapies targeting developmental pathways on
cancer stem-like cells and treatment outcome.
110 Nwabo Kamdje et al. Developmental pathways and cancer metastasis
the metastatic journey, i.e., from the primary site to the target
tissue invasion and secondary tumor development12-16.
EMT
EMT is a reversible specialized process that occurs during the
normal  embryonic  development,  which  is  pivotal  for  cell
specialization and tissue patterning. During development, an
early detachment of embryonic epithelial cell from the initial
tissue  occurs  without  activation of  anoikis.  Then,  these  cells
acquire  the  motile  shape  that  will  allow  them  to  migrate  to
new sites, where they will undergo mesenchymal-to-epithelial
transition,  providing  these  cells  with  the  capability  to  build
new  tissues21,22.  This  process,  which  also  occurs  during
wound  healing,  is  used  by  transforming  cells  during
tumorigenesis  and  tumor  progression.  Primary  tumor  cells
undergo  EMT  during  cancer  progression,  which  confers
them with a mesenchymal-like phenotype associated with not
only  high  motility  but  also  resistance  to  anoikis  and
anticancer drugs22-24.
While  normal  development  of  EMT  is  controlled  and
highly organized, this event is more stochastic in cancer25.
Physiological  EMT results  from the  coordination of  mo-
lecular events with new cell capacity. Specifically, EMT starts
by  losing  the  cell  junction  proteins,  such  as  E-cadherin,
claudins,  occludins,  and  catenins,  associated  with  the
epithelial organization, followed closely by the expression of
mesenchymal markers, such as N-cadherin and vimentin26,27.
A large number of oncogenic factors known to induce and/or
to  sustain  tumor  cell  motility  and  metastasis,  such  as
transforming growth factor beta (TGF-β) and insulin-like
growth factor 1, induce the loss of the epithelial marker E-
cadherin28,29. E-cadherin is at the center of EMT and anoikis
signaling  networks  because  its  loss  is  common in  cancer
progression, where this marker is associated with aberrant
EMT, tumor cell migration and invasion, and resistance to
anoikis. Moreover, the loss of E-cadherin and other adheren
junction molecules disrupts epithelial tissue, leading cells to
the adoption of a minimally polarized phenotype with high
invasive  properties.  The  switch  in  cell  morphologies  and
properties is mediated by key transcription factors, namely,
EMT-activating transcription factors. Examples include the
transcription factors of a snail family (e.g., snail, slug, and
smuc),  zinc-finger E-box-binding (ZEB) factors  [e.g.,  the
two-handed zinc-finger factors of d-crystallin/E2 box factor
(dEF1) family proteins dEF1/ZEB homeobox 1 and Smad-
interacting  protein  1/ZEB2],  and  basic  helix-loop-helix
factors (e.g., Twist1, Twist2, E12, E47, and Tbx3)30-32.
Motility and migration
The  metastatic  competent  cells  detached  from  primary
tumors  require  being  migrated  to  invade  other  sites.  The
migration  and  other  motility  events  result  from  specific
cytoskeletal changes mediated and regulated mainly by small
GTPase proteins of the Rho family33-36.  The members of the
Rho  GTPase  family  process  extracellular  signal  into  in-
formation  that  will  lead  to  the  reorganization  of  the  cy-
toskeleton.  As  discussed  above,  the  molecular  events  that
trigger  EMT  and  confer  anoikis  can  activate  the  migratory
machine  in  tumor  cells  through  the  members  of  the  Rho
GTPase family35.
Mounting evidence supports Rho GTPase involvement in
all tumorigenic events from the primary tumor initiation to
the metastasis. These small GTPases direct actin dynamic and
protrusive  patterns  in  migrating  cells,  including  the
projection of the cytoskeletal protein actin on the leading
edge  of  the  cell  (lamellipodia),  the  extension  of  slender
cytoplasmic  projections  beyond  the  leading  edge  of
lamellipodia  (filopodia),  and  the  extracellular  matrix
degradation-associated protrusions of the plasma membrane
(invadopodia)36.  Actin  dynamic  results  from  its  poly-
merization induced by actin-related protein 2 (Arp2) and
Arp3. Invadopodia is a characteristic of invasive tumor cells,
whereas the other patterns can occur in normal processes37-40.
Rho-A,  Cdc42,  and  Rac1  are  the  most  documented  Rho
GTPases involved in cell migration and metastasis. Besides
these common properties, Rho-A is also linked to stress fiber,
whereas  Cdc42  and  rac1  are  involved  in  filopodia  and
lamellipodia, respectively37,38.
In  addition  to  the  EMT-induced  protrusive  processes,
migrating  tumor  cells  can  undergo  collective  amoeboid
transition and mesenchymal to amoeboid transition with
characteristic invadopodia39,40. Notably, such invadopodia
require the enzymatic digestion of the extracellular matrix by
the  leading edge,  mediated by matrix  metalloproteinases.
This  type of  migration is  observed in many solid tumors,
including breast carcinoma41.
Neoangiogenesis
The  angiogenic  processes  triggered  during  tumorigenesis,
namely,  neoangiogenesis,  provide  the  neoplastic  tissue  with
new  blood  vessels  that  will  supply  the  high  requirements  of
this  tissue  in  nutrients  and  oxygen.  Such  high  requirements
are  triggered  by  paracrine  growth  signaling  aberrantly
activated  directly  or  indirectly  in  transforming  cells  in
response to extracellular matrix digestion41,42. The new blood
vessels  are  also  used  as  highways  by  invading  tumor  cells,
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which  are  able  to  travel  great  distances  in  the  body  to  start
metastases  in  other  organs  because  of  the  motility  provided
by EMT.
Neoangiogenic  dynamic  relies  on  angiogenic  signaling
molecules of the VEGF family (VEGF-A/B/C/D) and their
receptors (VEGFR-1/2/3/4)43,44.  The main activator of the
angiogenic cascade in the transforming and neoplastic tissue
is the hypoxic microenvironment. The low oxygen tension
observed in the microenvironment induces the stabilization
of  hypoxia-inducible  factors  (HIFs),  preventing  the  von
Hippel-Lindau  binding  protein-mediated  degradation  of
these transcription factors. Then, the HIFs enter the tumor
cell nuclei, where they dimerize and associate with p/300 to
form a transactivation complex. Consequently, this trans-
criptional complex will stimulate the expression of hypoxia
target genes by binding to their hypoxia response elements.
Hypoxia  target  genes  include  genes  involved  in  the
angiogenesis cascade, such as VEGF system genes, and other
ligand-receptor systems with high angiogenic potential, such
as  angiopoetin/Tie2,  platelet-derived  growth  factor
(PDGF)/PDGF receptor, Delta-like ligand 4 (DLL4)/Notch,
and fibroblast growth factor (FGF)/FGF receptor45-47.
Notch signaling and metastasis
Notch family of signaling molecules
The  Notch  family  of  the  transmembrane  proteins  en-
compasses  four  receptors  (Notch1-4)  and  five  ligands
(Jagged1/2,  Dll-1/3/4).  The  Notch  receptors  are  activated
when they bind to a ligand expressed on the membrane of an
adjacent  cell.  Then,  the  receptors  undergo  two  proteolytic
cleavages  at  S2  and  S3  sites  performed  by  ADAM10/17
metalloprotease  and  gamma  secretase  complex,  respectively.
The  two  proteolytic  events  result  in  the  release  of  an
intracellular  active  form  of  the  receptors,  namely,  Notch
intracellular  domain  (NICD).  Subsequently,  the  NICD
domains enter the nucleus, where they form a transcriptional
activation complex  with  MALM1 and RBP-jk  proteins.  This
complex  will  promote  the  expression  of  various  genes
involved  in  cell  fate  determination,  including  myc,  cyclinD,
and  genes  of  the  helix  basic  family,  such  as  hes1  and  hey1.
Functionally,  the  products  of  this  transcription  will  control
the  cell  proliferation,  cell  death,  adhesion,  invasion,  and
migration.
Notch in the metastatic cascade
The  survival  pathways  of  Notch  signaling  controls  are
important  for  anoikis  resistance,  such  as  NF-κB,  Akt,  Sat3,
and  mTOR31.  The  capability  to  modulate  the  expression  of
the  EMT  transcription  factors,  such  as  snail,  slug,  ZEB1/2,
TGF-β,  FGF,  and  PDGF,  increases  the  expression  of  the
mesenchymal markers (e.g., slug), downregulates the epithe-
lial  markers,  and  activates  the  Rho  GTPases3,18,48.  For
example,  Kwon  et  al.7  assessed  the  Notch  signaling's  pro-
metastatic  role  in  a  mouse  model  of  prostate  cancer.  The
constitutive expression of the Notch1 intracellular domain in
mouse  prostate  luminal  cells  (i)  impaired  secretory  func-
tions; (ii) suppressed anoikis via hes1  non-dependent NF-κB
activity;  and  (iii)  stimulated  luminal  cell  proliferation  by
potentiating  PI3K/Akt  signaling.  Recently,  Shao  and  col-
laborators38  emphasized  the  Jagged1-induced  Notch
signaling  triggered  migration,  invasion,  and  a  slug-de-
pendent  EMT  transition  in  breast  cancer  cells.  All  these
effects  were  abrogated  by  Notch  silencing48,  underlining  the
potential of Notch targeting for the modulation of tumor cell
motility. Furthermore, Rho GTPase upregulation is common
in  patients  diagnosed  with  T-cell  acute  lymphoblastic
leukemia (T-ALL), a hematological malignancy, where Notch
activating  mutations  are  observed  in  more  than  50%  of  the
cases49.
Notch targeting as antimetastatic strategy
Notch-based therapeutic strategies
Notch-based  therapeutic  strategies  were  developed  for  var-
ious steps of the signaling cascade, including ligand-receptor
interactions,  enzymatic  cleavages  of  the  receptors,  cy-
toplasmic  interactions,  and  transcriptional  activation  com-
plex.  The  requirement  of  S2  and  S3  cleavages  for  the
activation of  Notch receptors  made these  events  particularly
attractive for the modulation of Notch-induced repression of
E-cadherin,  which  associates  with  a  number  of  pro-tumor-
igenic  events  and  poor  prognosis  in  solid  cancers,  such  as
breast  cancer50.  S2  and  S3  are  due  to  ADAM10/17
metalinebreak and secretase complex, respectively. Unlike S2
cleavage  inhibitors,  gamma  secretase  inhibitors  (GSI)  have
been  widely  used  in  anticancer  preclinical  research,  partly
due  to  GSIs  were  developed  first  and  tested  in  Alzheimer’s
disease  and  experimental  models,  where  they  proved
relatively  safe51.  GSIs  achieving  a  total  blockade  of  Notch
signaling  display  strong antineoplastic  responses,  while  even
those  achieving  partial  blockade  can  exhibit  decent
antineoplastic activities52,53.
GSI treatment mitigated the development of tumor cell
invasion and metastasis in vivo  and in vitro  by preventing
EMT, migration, invasion, and neoangiogenesis54. A number
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of GSIs recently entered clinical trials, including BMS906024,
MK0752,  PF03084014,  and  R0492909755.  PF03084014  is
currently  in  phase  1  trials  in  metastatic  pancreatic  ad-
enocarcinoma patients not previously treated with anticancer
therapies.  R04929097  is  in  phase  2  trials  in  metastatic
melanoma56.  MK0752  is  in  phases  1  and 2  trials  for  me-
tastatic and advanced primary tumors, respectively, in breast
cancer55.  Moreover,  blocking antibodies with GSI activity
have  also  been  developed.  These  agents  target  the
components of GSI complex, such as nicastrin, the largest
member  of  the  complex.  Antinicastrin  monoclonal
antibodies  clone  2H6  elicited  pleiotropic  antimetastatic
activities  on  invasive  cancer  cell  lines,  including  an
attenuation of invadopodia degradation of the extracellular
matrix  and  delayed  cancer  cell  extravasation  through
endothelial  cells  in the in vitro  Boyden chamber invasion
assay57.
The  enthusiasm  for  anticancer  and  antimetastatic
application of GSIs is mitigated by the limitation to gamma
secretase  targeting,  considering  that  this  Notch signaling
component  is  not  always  critical  in  the  pathological
phenotype of malignancies. In addition, a number of tissues
physiologically require Notch activity for tissue plasticity.
Gastric  epithelium  is  the  most  relevant  example  of  such
tissue.  Its  functional  alterations  partly  explain  the
gastrointestinal  toxicity  observed  following  GSI  treat-
ment53,55,56.  In  vivo  experiments  suggest  that  currently,
antinicastrin monoclonal antibodies are more potent than
GSIs in clinical trials, with minimally marked gastrointestinal
signs57.  Collectively,  these  observations  suggested  the
possibility  to  improve  the  therapeutic  outcome  of  the
targeting of Notch signaling by changing the specific targets
and the approaches used. These findings raised the question
of  whether  developing  the  inhibitors  for  specific  Notch
receptors  or  ligands  would  also  improve  therapeutic
outcome.
Targeting Notch ligands and receptors
Notch  ligand  and  receptor  targeting  is  a  particularly  in-
teresting  approach  because  it  allows  specific  targeting  of
Notch  receptors  or  ligands  critical  in  the  pathological  phe-
notype of  malignancies,  including the metastatic  phenotype.
For  example,  Notch1  was  reported  to  control  metastatic
processes  in  small  cell  lung  cancer  cell  lines  and  to  initiate
EMT and invasion of breast cancer cells48,58. The targeting of
blocking  monoclonal  antibodies,  specifically  Notch  receptor
subtypes, has been developed. These molecules mainly act on
the  EGF-like  repeats  of  Notch  receptors.  Various  Notch
receptor  blocking  antibodies  have  entered  clinical  trials  for
metastatic  and  advanced  solid  cancers.  For  example,
tarextumab  (OMP-59R5),  an  anti-Notch2/3  receptor  cur-
rently  in  phase  1  trials  in  patients  with  untreated  metastatic
pancreatic  cancer,  is  showing  promising  therapeutic  effects
with the antineoplastic (chemotherapy) drugs Nab-Paclitaxel
and  Gemcitabine59.  Examples  of  other  Notch  receptor  or
ligand blocking antibodies  currently  in clinical  trials  include
Notch1 monoclonal antibody OMP-52M5 and the anti-DLL4
demcizumab (OMP-21M18)55.
Besides,  small  molecules  acting  as  receptor  or  ligand
decoys  were  also  developed.  A  recent  report  by  Kang-
samaksin and collaborators10 provided experimental evidence
for the potential of decoy molecules for silencing the Notch
receptors and ligands specifically60. These authors developed
Notch decoys N1-13 and N1-24, interfering with Dll-Notch
and  Jagged-Notch  interactions,  respectively.  The  decoy
molecules potently disrupted tumor growth and promoted
normal endothelial sprouting in tumor microenvironment by
reducing angiogenic sprouting, vessel perfusion and pericyte
coverage, and other pro-angiogenic processes54. Besides the
possibility  to  improve  the  therapeutic  outcome,  Notch
receptor or ligand-specific targeting may also decrease the
severity or abrogate adverse gastrointestinal effects observed
with the unspecific targeting of Notch signaling.
Antimetastatic potential of Wnt and
Hedgehog targeting
Wnt targeting
Wnt signaling and cancer
The Wnt family of signaling molecules encompasses a num-
ber of cysteine-rich glycosylated secreted ligands that bind to
the extracellular domain of frizzled family of receptors.  Wnt
binding triggers a signaling cascade resulting in the activation
of  genes  involved  in  stem  cell  maintenance,  cell  survival,
proliferation,  motility,  migration,  and  fate  determination
during  the  development.  Wnt  aberrant  overexpression  can
activate  the  pathogenic  developmental-like  Wnt  signaling
activity  in  transforming  cells,  favoring  stemness  and
chemotherapy resistance61-63.
The canonical Wnt/β-catenin pathway is the most studied
Wnt  signaling  pathway.  In  the  canonical  pathway,  Wnt
binding to frizzled-7 leads to the disaggregation of β-catenin
destruction  complex  made  of  the  tumor  suppressor
adenomatous  polyposis  coli  (APC),  the  serine/threonine
protein kinase glycogen synthase kinase 3, and casein kinase.
Canonical Wnt/β-catenin pathway requires the co-receptors
LRP5 and LRP6. The disaggregation of β-catenin destruction
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complex results in the inhibition of β-catenin destruction,
and  conversely,  in  the  cytoplasmic  accumulation  of  β-
catenin.  When  in  sufficiently  high  levels,  a  fraction  of
cytoplasmic  β-catenin  migrates  to  the  nucleus  where  it
interacts  with  a  member  of  the  TCF/LEF-1  family  of
transcription  factors.  Consequently,  these  transcription
factors activate gene encoding for proteins involved in EMT,
survival, angiogenesis motility, and invasion, such as c-Myc,
Jagged1,  VEGF,  CCL2,  snail,  slug,  vimentin,  and  met-
alloproteinases62-67.
Two other Wnt signaling pathways, i.e., the non-canonical
Wnt  pathways,  namely,  the  planar  cell  polarity  and
Wnt/calcium pathway, were also described. The Wnt non-
canonical pathway does not require the co-receptors LRP5/6.
The non-canonical planar polarity pathway activates small
Rho GTPases, such as RAC1, Rho, and Cdc42, which control
actin dynamic through Rho kinase, the actin-binding protein
cofilin, and the MAPK kinase JNK68-71.
The Wnt/calcium pathway, which is initiated by non-ca-
nonical  Wnt  ligands,  such  as  Wnt5a,  activates  phos-
phoinositide phospholipase C (PLC) and phosphodiesterase
6  (PDE6).  The  PLC-mediated  cleavage  of  the  plasma
membrane  phospholipid  phosphatidylinositol  4,5-bis-
phosphate releases inositol trisphosphate and diacylglycerol.
The  resulting  signaling  cascades  induce  the  release  of
mitochondrial  Ca2+  in  the  cytoplasm,  with  subsequent
activation  of  Ca2+-dependent  enzymes,  such  as  Ca2+/
calmodulin-dependent kinase II,  protein kinase C (PKC),
and  the  serine/threonine  protein  phosphatase  calcin-
eurin68-71.
Role of Wnt signaling in metastasis and therapeutic
potential
Evidence  sustaining  a  role  for  aberrant  Wnt  pathway
activation  in  metastasis  was  provided  by  reports  of  the
capability of Wnt antagonism to suppress tumorigenesis and
metastasis partly (i) by enhancing the expression of epithelial
marker,  such  as  E-cadherin  and  keratin  8/18  (preventing
EMT) and (ii) by decreasing the expression of pro-metastatic
factors,  such  as  slug,  twist,  snail,  and  metalloproteinases8-10.
The  aberrant  accumulation  of  β-catenin  in  the  cytoplasm
observed in  colorectal  tumors  and many other  solid  cancers
results  from  tumor-promoting  epigenetic  events,  such  as
DNA  demethylation  on  a  CTNNB1  gene  promoter  that
activates β-catenin synthesis, and DNA hypermethylation on
an APC gene promoter that silence this gene, resulting in the
decrease  of  cellular  levels  of  β-catenin  destruction  complex
member APC70,71.  Similarly,  the absence of degrading the β-
catenin  observed  in  many  cancers  may  also  result  from  the
silencing  mutations  of  APC  gene,  whereas  the  activating
mutations of  CTNNB1  gene may also increase the β-catenin
cellular  levels72,73.  The genetic  and epigenetic  suppression of
the  other  members  of  the  destruction  complex  was  also
reported74,75.  Furthermore,  a  fraction  of  β-catenin  is  bound
to  the  E-cadherin  in  the  cytoskeleton,  thus  the  EMT-
associated  loss  of  E-cadherin  results  in  the  release  of  β-
catenin76.  The  failure  of  misshaped  β-catenin  (product  of
mutations) to bind to E-cadherin also increases the β-catenin
cytoplasmic levels.
The canonical  Wnt3 signaling consistently  promoted a
partial EMT-like transition with increased N-cadherin, twist,
slug, and decreased E-cadherin in the trastuzumab-resistant
breast  tumor  cells,  and  the  Wnt3  knockdown  by  siRNA
decreased the expression of EMT triggering factor EGFR in
these malignant cells77. In addition, activating the Wnt /β-
catenin signaling correlates with EMT and the potency of
proliferation and invasiveness in prostate cancer cells63,78.
The nuclear localization of β-catenin is a molecular marker
of EMT in colon cancer79. The inhibition of Wnt signaling
with  β-catenin  shRNA reversed  HIF-1α-induced EMT in
human prostate cancer63,78. Moreover, Wnt/β-catenin may
promote  EMT  via  direct  transactivation  of  EMT  trans-
cription factors, such as ZEB131.
The non-canonical  Wnt signaling pathways also played
pivotal  roles  in  cancer  metastasis.  For  example,  the  well-
known  activator  of  non-canonical  Wnt  pathway  Wnt5a
increased not  only  the  metastasis  in  a  PKC- and a  Stat3-
dependent manner in melanoma but also the expression of
melanoma  immunogens  and  severity  markers  GP100,
MART-1, and tyrosinase80,81.
Wnt5a  is  upregulated  in  epithelial  tumors,  where  it
promotes EMT and migration in a β-catenin-independent
manner82-89. The treatment of these tumor cells with Wnt5a
resulted  in  an  upregulation  of  EMT  stimulating  factors,
including vimentin, Snail1, and slug82.  In addition, Gujral
and  collaborators104  reported  an  upregulation  of  Wnt5
receptor Frizzled2 in metastatic liver, lung, colon, and breast
cancer cell lines and in high-grade tumors. Such expression
correlated with the overexpression of EMT markers. In the
same  study,  pharmacological  and  genetic  perturbation
analyses suggested that Wnt5a/Frizzled2 signaling induces
EMT  and  cell  migration  via  a  previously  unrecognized
Fyn/Stat3-dependent non-canonical pathway.
Besides,  considering the involvement of planar polarity
pathway in regulating actin cytoskeleton mediated via  its
capability to activate the Rho GTPases (Section 2.3.1)68-70, a
role for this non-canonical Wnt pathway in the cytoskeleton
reorganization supporting motility, migration, and invasion
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can be predicted.  The experimental  evidence suggests  the
involvement  of  this  pathway  in  cellular  motility  and  the
invasive capacity of metastasis-promoting cells  in various
cancers,  including pancreatic ductal  adenocarcinoma and
breast  cancer85,86.  Moreover,  Frizzled  receptors  that  can
trigger  canonical  and  non-canonical  signaling,  such  as
Frizzled2 and Frizzled7, reported the capability to interact
with  Rho-A  and  other  small  GTPases  during  metastatic
cascade. For example, Wnt3a/Frizzled2 signaling stimulates
cell migration and invasion in a Rho-A-dependent manner in
multiple myeloma83,84, and Wnt5a was reported to promote
cell  migration  in  breast  cancer  through  the  Dishev-
elled2/Daam1/Rho-A axis89.
The canonical Wnt signaling pathway inhibitors, such as
the CBP/β-catenin antagonist PRI-724, have been developed.
The pivotal roles of this signaling pathway in maintaining the
stemness  of  tissue  stem cells  and  in  regulating  the  tissue
homeostasis and cell fate along the lifespan raise concerns for
safety of Wnt-based anticancer strategies despite the potential
of  Wnt  signaling  targeting  for  cancer  stem  cell  elimina-
tion90,91  and  metastasis  suppression,  discouraging  their
development. Preclinical studies91 and phase 1 clinical trials92
suggested that PRI-724 is relatively well-tolerated, and the
drug  is  currently  in  phase  2  trials  combined  with  che-
motherapy drugs and the angiogenesis inhibitor bevacizumab
(NIH  t r ia l  IDs  3C-13-3 ,  NCI-2015-00436 ,  and
NCT02413853). Experimental evidence suggests differences
in Wnt signaling mediating stemness in malignant and non-
malignant cells93.  The characterization of such differences
may open new avenues for safe targeting of Wnt signaling.
Hedgehog, metastatic cascade, and emerging
therapies
Hedgehog family
The  vertebrate  Hedgehog  family  of  lipid-modified  proteins
encompasses  Desert  Hedgehog,  Indian  Hedgehog,  and  Shh.
Shh is the most studied Hedgehog family member. Hedgehog
proteins  are  the  ligand  of  12-pass  transmembrane  protein
receptors,  namely,  patched.  In  the  absence  of  interactions
with  ligands,  patched  receptors  catalytically  maintain  the  7-
pass  transmembrane  protein  smoothened  (Smo)  in  an
inactive state. The inhibitory activity of patched is abrogated
upon  ligand  binding,  and  Smo  activates  the  transcription
factors  of  Gli  zinc-finger  protein  family  in  the  cytoplasm.
Then,  Gli  proteins  migrate  to  the  nucleus  where  they
transactivate or repress various genes94,95.
Hedgehog played pivotal roles in cancer development96
and in metastatic cancer. For example, the loss and gain and
pharmacological  inhibitions  of  function  experiments
suggested  that  Hedgehog  signaling  is  required  along  the
metastatic cascade97-101. Examples include studies showing (i)
that  high  Hedgehog-Gli  signatures  coincide  with  the
development of metastases in colon cancer98  and (ii) that
Gli1  transcription  factor  activity  links  with  tumor  ag-
gressiveness  in  papillary  thyroid  cancer97.  In  addition,
Hedgehog promotes EMT in various solid tumors, including
pancreatic,  colon,  and  breast  cancers99.  Gli  proteins  are
involved  in  the  TGF-β  mediated  EMT  in  hepatocellular
carcinoma, marked by an increased expression of Snail1101.
The Gli1 knockdown resulted in decreased hepatocellular
carcinoma  migration  and  invasion101.  Shh  enhanced  the
gastric  cancer  cell  motility  and  invasiveness,  whereas  no
increase  was  observed  in  cells  treated  with  Shh signaling
inhibitor  cyclopamine-KAAD  or  anti-Shh  monoclonal
antibodies100.  Moreover,  Yoo  and  collaborators105  dem-
onstrated  that  Shh  signaling  promotes  gastric  cancer
metastasis at least partly through the activation of PI3K/Akt
signaling-mediated matrix metallopeptidase 9 and EMT.
Hedgehog-based therapeutic strategies
The  Smo  inhibitors  are  the  largest  group  of  Hedgehog
signaling  inhibitors.  The  naturally  occurring  alkaloid  cyc-
lopamine  is  a  typical  example.  Cyclopamine  inhibits  the
growth  and  invasiveness  of  a  tumor  cell  in  vitro  and  in
vivo103-105.  However,  the  translation  to  cancer  treatment  has
been  challenging  due  to  the  poor  stability  and  solubility  of
cyclopamine  and  also  due  to  its  severe  adverse  effects  re-
sulting  from  the  activity  of  the  products  of  its  metab-
olism101,106.  Soluble  and  stable  derivatives  of  cyclopamine
were  developed,  including  (i)  the  emerging  prodrug  cyc-
lopamine  glucuronide  tested  in  glioblastoma  multiform
models107  and  (ii)  vismodegib  (GDC-0449),  currently  in
phase  2  clinical  trials  in  patients  with  metastatic  pancreatic
adenocarcinoma108, advanced primary tumors and metastatic
basal cell carcinoma109,  and pediatric brain tumors110.  Other
Smo inhibitors,  currently  in  clinical  trials  for  refractory  and
metastatic  cancer  treatment,  include  IPI-926111,  LDE225112,
BMS-833923113,  and  PF-0449913114.  Most  of  these  prodrugs
and  drugs  have  an  acceptable  safety  profile  with  only  low
grade  or  relatively  minor  adverse  effects  with  promising
anticancer  and  antimetastatic  effects.  Moreover,  Gli
inhibitors,  another  class  of  Hedgehog  inhibitors,  include
prodrugs,  such  as  Gant-58  and  Gant-61,  which  displayed  a
strong antimetastatic potential in preclinical studies100-123.
A  number  of  blocking  antibodies  targeting  Hedgehog
signaling  are  available,  while  only  a  few  inhibitors  of
Hedgehog ligands were developed. The monoclonal antibody
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5E1, one of the most studied Hedgehog-targeting antibodies,
antagonizes  the  three  Hedgehog ligands.  Studies  in  nude
mice revealed 5E1 capable  of  inhibiting the  metastasis  of
pancreatic  cancer118.  The  Hedgehog  ligand  inhibitor
robotnikinin was discovered by Stanton and collaborators102
using  approaches  for  small  molecule  microarrays  and
diversity-oriented synthesis. This small molecule mediates
extracellular  Shh  inhibition  by  binding  to  this  protein,
preventing  interactions  with  patched  receptors.  Data  on
robotnikinin effects on metastatic processes are lacking.
Conclusions
Targeted therapies based on emerging master developmental
pathways  represent  promising  approaches  for  metastasis
prevention  and  cancer  stem  cell  elimination.  Such  ther-
apeutic  potential  is  due  to  the  tumorigenesis-mediated  hi-
jacking  of  EMT,  cell  motility,  migration,  stemness,  angio-
genesis,  and  other  key  phenomena  determining  cell  fate
controlled  by  developmental  pathways.  These  phenomena
are  pivotal  for  all  steps  of  solid  tumor  initiation,  main-
tenance, and development. Various classes of Notch signaling
inhibitors are currently in clinical trials. The development of
therapeutics  targeting  specifically  the  Notch  signaling
components  critical  for  malignancy  pathological  phenotype
is expected to improve the therapeutic outcome and decrease
adverse  effects.  Wnt  signaling  targeting,  in  which  safety  is  a
serious concern, is surprisingly well-tolerated in clinical trials
and  is  expected  to  be  a  game  changer  for  cancer  stem  cell
elimination  and  metastasis  prevention.  Unlike  Notch  and
Wnt  pathways,  translating  the  Shh  signaling  blockade  to
cancer  treatment  has  been  challenging  because  of  severe
adverse  effects  and  poor  therapeutic  potential  of  various
monoclonal  antibodies  and  naturally  occurring  Smo
inhibitors. Further mechanistic studies of the involvement of
developmental pathways in refractory and metastatic cancers
may  further  improve  the  targeting  efficiency  and  the
therapeutic outcome.
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